FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340372500> ?p ?o ?g. }

• W2340372500 endingPage "238" @default.
• W2340372500 startingPage "233" @default.
• W2340372500 abstract "<h3>Objectives</h3> To explore the use of intraperitoneal chemotherapy in conjunction with cytoreductive surgery for the treatment of peritoneal surface malignancy and highlight the challenges this provides for the hospital pharmacist. <h3>Methods</h3> A literature search for relevant articles was performed using MEDLINE, PubMed and Cochrane databases. The following keywords and phrases were used: ‘hyperthermic intraperitoneal chemotherapy’, ‘early postoperative intraperitoneal chemotherapy’, ‘carrier solutions’ and ‘cytoreductive surgery’. Local experience was also shared, referencing national guidelines and published literature. <h3>Results</h3> The rationale behind intraperitoneal chemotherapy is to directly administer drugs into the peritoneal cavity and achieve exposure of higher concentrations of cytotoxic agents to tumour nodules within the abdomen and on peritoneal surfaces for a prolonged period of time, without significant systemic toxicity. This has been widely demonstrated in intraoperative and early postoperative settings. Hydrophilic chemotherapy drugs with high molecular weights and permeable to the peritoneum, but slow plasma clearance create high concentrations of the drug in the peritoneal cavity, with lower systemic circulation. Commonly used drugs include <i>mitomycin C</i>, <i>oxaliplatin</i>, <i>cisplatin</i>, <i>doxorubicin</i> and <i>5-fluorouracil</i>. Newer drugs such as the taxanes and <i>bevacizumab</i> have also shown promise. Heat increases drug penetration into body tissues and destroys tumour cells directly by causing damage to cells that have inherently faulty heat regulation pathways and also increases the cytotoxic effect of selected chemotherapeutic agents. Optimal temperature for hyperthermic intraperitoneal drug administration is between 41 and 43°C in a carrier solution that is compatible with the drug chosen. For early postoperative intraperitoneal chemotherapy high molecular weight starch carrier solutions prolong intraperitoneal dwell time and exposure of drug to tumour cells. Drugs are administered intraoperatively with the abdomen open or closed for between 30 and 120 min depending on the drug chosen and local protocols. Drug doses are traditionally calculated using body surface area. Toxicity such as neutropenia is encountered far less than with systemic chemotherapy. <h3>Conclusions</h3> This paper discusses the rationale for intraperitoneal drug administration following cytoreductive surgery and describes appropriate drug selection, methods of drug delivery and potential challenges in the use of the intraperitoneal route. It provides evidence and practical guidance for hospital pharmacists who may be involved in the surgical management of peritoneal malignancy particularly in dose calculation, preparation and administration of intraperitoneal chemotherapy." @default.
• W2340372500 created "2016-06-24" @default.
• W2340372500 creator A5003909391 @default.
• W2340372500 creator A5016373224 @default.
• W2340372500 creator A5022831790 @default.
• W2340372500 creator A5078581983 @default.
• W2340372500 creator A5086442158 @default.
• W2340372500 date "2016-04-05" @default.
• W2340372500 modified "2023-09-27" @default.
• W2340372500 title "Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective" @default.
• W2340372500 cites W1969667718 @default.
• W2340372500 cites W1976501641 @default.
• W2340372500 cites W1983329768 @default.
• W2340372500 cites W1993986639 @default.
• W2340372500 cites W2036599004 @default.
• W2340372500 cites W2038476799 @default.
• W2340372500 cites W2038644401 @default.
• W2340372500 cites W2042210669 @default.
• W2340372500 cites W2044221999 @default.
• W2340372500 cites W2045712356 @default.
• W2340372500 cites W2060621506 @default.
• W2340372500 cites W2063287558 @default.
• W2340372500 cites W2063809375 @default.
• W2340372500 cites W2078239596 @default.
• W2340372500 cites W2089232138 @default.
• W2340372500 cites W2097108123 @default.
• W2340372500 cites W2114250143 @default.
• W2340372500 cites W2116274195 @default.
• W2340372500 cites W2122700913 @default.
• W2340372500 cites W2146533232 @default.
• W2340372500 cites W2150120491 @default.
• W2340372500 cites W2162553170 @default.
• W2340372500 cites W2164878282 @default.
• W2340372500 cites W2165857438 @default.
• W2340372500 cites W2166820203 @default.
• W2340372500 cites W2168912348 @default.
• W2340372500 cites W4254152694 @default.
• W2340372500 doi "https://doi.org/10.1136/ejhpharm-2016-000877" @default.
• W2340372500 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6451493" @default.
• W2340372500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31156855" @default.
• W2340372500 hasPublicationYear "2016" @default.
• W2340372500 type Work @default.
• W2340372500 sameAs 2340372500 @default.
• W2340372500 citedByCount "3" @default.
• W2340372500 countsByYear W23403725002017 @default.
• W2340372500 countsByYear W23403725002022 @default.
• W2340372500 countsByYear W23403725002023 @default.
• W2340372500 crossrefType "journal-article" @default.
• W2340372500 hasAuthorship W2340372500A5003909391 @default.
• W2340372500 hasAuthorship W2340372500A5016373224 @default.
• W2340372500 hasAuthorship W2340372500A5022831790 @default.
• W2340372500 hasAuthorship W2340372500A5078581983 @default.
• W2340372500 hasAuthorship W2340372500A5086442158 @default.
• W2340372500 hasBestOaLocation W23403725002 @default.
• W2340372500 hasConcept C121608353 @default.
• W2340372500 hasConcept C126322002 @default.
• W2340372500 hasConcept C141071460 @default.
• W2340372500 hasConcept C143998085 @default.
• W2340372500 hasConcept C2776694085 @default.
• W2340372500 hasConcept C2778536324 @default.
• W2340372500 hasConcept C2779338040 @default.
• W2340372500 hasConcept C2779458272 @default.
• W2340372500 hasConcept C2780427987 @default.
• W2340372500 hasConcept C2780962732 @default.
• W2340372500 hasConcept C2994223192 @default.
• W2340372500 hasConcept C3019901188 @default.
• W2340372500 hasConcept C526805850 @default.
• W2340372500 hasConcept C71924100 @default.
• W2340372500 hasConcept C98274493 @default.
• W2340372500 hasConceptScore W2340372500C121608353 @default.
• W2340372500 hasConceptScore W2340372500C126322002 @default.
• W2340372500 hasConceptScore W2340372500C141071460 @default.
• W2340372500 hasConceptScore W2340372500C143998085 @default.
• W2340372500 hasConceptScore W2340372500C2776694085 @default.
• W2340372500 hasConceptScore W2340372500C2778536324 @default.
• W2340372500 hasConceptScore W2340372500C2779338040 @default.
• W2340372500 hasConceptScore W2340372500C2779458272 @default.
• W2340372500 hasConceptScore W2340372500C2780427987 @default.
• W2340372500 hasConceptScore W2340372500C2780962732 @default.
• W2340372500 hasConceptScore W2340372500C2994223192 @default.
• W2340372500 hasConceptScore W2340372500C3019901188 @default.
• W2340372500 hasConceptScore W2340372500C526805850 @default.
• W2340372500 hasConceptScore W2340372500C71924100 @default.
• W2340372500 hasConceptScore W2340372500C98274493 @default.
• W2340372500 hasIssue "4" @default.
• W2340372500 hasLocation W23403725001 @default.
• W2340372500 hasLocation W23403725002 @default.
• W2340372500 hasLocation W23403725003 @default.
• W2340372500 hasLocation W23403725004 @default.
• W2340372500 hasOpenAccess W2340372500 @default.
• W2340372500 hasPrimaryLocation W23403725001 @default.
• W2340372500 hasRelatedWork W1880092793 @default.
• W2340372500 hasRelatedWork W2340372500 @default.
• W2340372500 hasRelatedWork W2385635703 @default.
• W2340372500 hasRelatedWork W2467630816 @default.
• W2340372500 hasRelatedWork W2509184249 @default.
• W2340372500 hasRelatedWork W2904799830 @default.
• W2340372500 hasRelatedWork W3016586731 @default.

• next